A 29-year-old woman was diagnosed with Flt-3-positive AML. In August 2004, she received allogeneic HSCT from her HLA-identical sister after a myeloablative-conditioning regimen. CsA and MTX were used for GvHD prophylaxis.
One month after the engraftment and achievement of complete donor chimerism, the patient developed a steroidrefractory acute GvHD (grade IV) of liver and gut, which was successfully treated with sequential combinations of different immunosuppressive drugs (prednisolone, tacrolimus, etanercept, daclizumab, ATG and MMF), resulting in remission of GVHD. In June 2005, immunosuppression could be tapered and stopped. In September 2005, chronic cutaneous GvHD was diagnosed and initially treated with topical steroids. During the following 2 months, GvHD progressed, involving the whole integument in a lichenoid and sclerodermiform manner, requiring again systemic immunosuppression with prednisolone and tacrolimus. Despite different treatment lines with rituximab, MMF, everolimus and MTX, the therapy-refractory cutaneous GvHD further progressed, resulting in extensive ulceration of the scalp (12 Â 17 cm) until June 2008 ( Figure 1 ). As conservative treatment did not result in re-epithelialisation and was complicated by secondary infections, we performed a split-thickness skin grafting.
To avoid reactivation of GvHD, we decided to use an allogeneic skin graft from her HLA-identical sister. The first step of reconstitution consisted of wound debridement and a first meshed skin graft covering nearly 100% of the ulcerated area under continuous immunosuppression with prednisolone, MMF and MTX. Skin grafts were taken from the donor thigh under local anaesthesia by using an electric dermatome with a common cut depth of 0.3 mm. Grafts were applied after meshing to 1.5 times immediately to the ulcer base and secured with surgical staples at the wound edge. After 3 months, 50% of the wound area was covered by engrafted donor skin. After further wound debridement, the remaining ulcerated area was covered by a second step of split-thickness skin transplantation. This procedure resulted in complete healing of the large ulceration within 5 months (Figure 2 ). Interestingly, we were able to gradually taper systemic immunosuppression from prednisolone, MMF and MTX to MMF alone, without local or systemic deterioration of GvHD. Immunosuppression could be stopped completely in December 2010. The patient remains in CR concerning AML with complete donor chimerism and is full-time working without any symptoms of chronic GvHD.
In cases of skin ulceration due to chronic cutaneous GvHD after allogeneic HSCT, there are only a few reports in the current literature about treatment with skin transplantation. One of the earliest reports on treatment of ulcerating chronic GvHD with skin grafts from the BM donor was published by Knobler et al. 1 in 1985. Three further groups reported on successful allogeneic skin grafting in severe chronic GvHD from the HLA-identical stem cell donor.
2 --4 Recent data come from French colleagues who treated a patient for extensive-ulcerating cutaneous GvHD, with a twostep skin transplantation of the HLA-identical sister resulting in complete coverage of the skin lesion and subsequent withdrawal of immunosuppression. 5 Berg et al. 6 treated another female patient after allogeneic HSCT with severe cutaneous chronic GvHD of the scalp, with split-thickness skin transplantation of the HLAidentical sibling stem-cell donor under low-dose immunosuppression with prednisolone, resulting in complete engraftment of the graft.
Successful skin grafting from the stem-cell donor is of immunological interest. First, it clearly demonstrates that chronic GvHD is still a continuing alloreaction against recipient Ags, as dermal Ags are present in both donor and recipient skin. Second, our observations indicate not only absence of GvHD in the grafted skin, but suggest an additional immunomodulatory effect. The ability to taper systemic immunosuppression after skin grafting is compatible with potential induction of tolerance by migratory cells of the skin graft. This is in line with murine data, suggesting immunomodulating property via DCs in skin, which could lead to induction of regulatory T cells. 7, 8 In conclusion, we could show that in a case of treatmentrefractory, ulcerating chronic GvHD after allogeneic HSCT, splitthickness skin transplantation from the HLA-identical donor can be a successful permanent treatment option. Whether donor skin grafts exert a systemic immunomodulating effect remains speculative and needs further investigation.
